Base de dados : MEDLINE
Pesquisa : C04.557.470.615 [Categoria DeCS]
Referências encontradas : 70 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 7 ir para página                  

  1 / 70 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26469932
[Au] Autor:Stewart J; Monti P
[Ad] Endereço:Centre of Preventative Medicine, Animal Health Trust, Newmarket, UK.
[Ti] Título:What is your diagnosis? Perianal mass in a dog.
[So] Source:Vet Clin Pathol;44(4):615-6, 2015 Dec.
[Is] ISSN:1939-165X
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Adenoma/veterinária
Neoplasias das Glândulas Anais/diagnóstico
Doenças do Cão/diagnóstico
[Mh] Termos MeSH secundário: Adenoma/diagnóstico
Adenoma/patologia
Neoplasias das Glândulas Anais/patologia
Animais
Doenças do Cão/patologia
Cães
Feminino
Neoplasias Ductais, Lobulares e Medulares/diagnóstico
Neoplasias Ductais, Lobulares e Medulares/patologia
Neoplasias Ductais, Lobulares e Medulares/veterinária
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1610
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151016
[St] Status:MEDLINE
[do] DOI:10.1111/vcp.12297


  2 / 70 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:25935968
[Au] Autor:Patel NS; Sisodia VK; Vadher SH
[Ti] Título:Role of sentinel lymph node biopsy in early breast cancer.
[So] Source:J Indian Med Assoc;112(2):110-2, 2014 Feb.
[Is] ISSN:0019-5847
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:Current literature has suggested that sentinel lymph node biopsy may replace axillary dissection as the nodal staging procedure of choice in early breast cancer. The aim of this study is to evaluate the effectiveness and accuracy of sentinel lymph node biopsy using methylene blue dye in predicting axillary nodal status in early breast cancer with clinically impalpable axillary lymph nodes. In the period between June 2005 and May 2009, 50 patients with early breast cancer and clinically impalpable axillary lymph nodes, underwent sentinel lymph node biopsy using methylene blue dye followed by completion of axillary dissection in the same setting after taking a written consent from the patients. Of the included 50 patients, sentinel lymph node biopsy was successful in 48 patients (96.0%). Accuracy of sentinel lymph node biopsy was 95.8%, sensitivity was 90.0%, false negative rate was 6.7%, negative predictive value was 93.3%.
[Mh] Termos MeSH primário: Neoplasias da Mama/patologia
Neoplasias Ductais, Lobulares e Medulares/patologia
Biópsia de Linfonodo Sentinela
[Mh] Termos MeSH secundário: Axila
Corantes
Feminino
Seres Humanos
Azul de Metileno
Meia-Idade
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Coloring Agents); T42P99266K (Methylene Blue)
[Em] Mês de entrada:1505
[Cu] Atualização por classe:150504
[Lr] Data última revisão:
150504
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150505
[St] Status:MEDLINE


  3 / 70 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23812457
[Au] Autor:Dimitrakakis C; Tsigginou A; Zagouri F; Marinopoulos S; Sergentanis TN; Keramopoulos A; Liakou P; Zografos GC; Papadimitriou CA; Dimopoulos MA; Antsaklis A
[Ad] Endereço:Department of Obstetrics and Gynecology, Alexandra Hospital, Medical School, University of Athens, Athens, Greece.
[Ti] Título:Breast cancer in women aged 25 years and younger.
[So] Source:Obstet Gynecol;121(6):1235-40, 2013 Jun.
[Is] ISSN:1873-233X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate breast cancer characteristics in women aged 25 years and younger. METHODS: This was a retrospective, nested, within-cases matched study. The study design was based on a two-phase protocol. In the first phase, stage, grade, histologic subtype, estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status were compared between 28 patients (aged 25 years and younger) and 685 older premenopausal women (aged older than 25 years) with breast cancer. The second phase aimed to determine whether young patients exhibited worse prognosis when compared with older premenopausal women. RESULTS: Young patients presented at a more advanced stage (P=.012) and exhibited a higher grade (P=.018). No significant differences were noted regarding histologic subtype, estrogen receptor, and progesterone receptor status. Genetic testing for BRCA1 and BRCA2 mutations was performed in 12 of 28 young patients and mutations were found in 25% of them. Moreover, young women presented poorer overall survival (hazard ratio [HR] 4.30, 95% confidence interval [CI] 1.09-17.03) than their older counterparts, matched by histologic subtype, stage, and grade; a similar pattern was noted regarding relapse-free survival (HR 8.28, 95% CI 2.24-30.60). CONCLUSION: Breast cancer diagnosis in women aged 25 years and younger is uncommon; however, these patients present at a more advanced stage, with a higher grade, and exhibit poorer survival.
[Mh] Termos MeSH primário: Neoplasias da Mama/epidemiologia
Neoplasias Ductais, Lobulares e Medulares/epidemiologia
[Mh] Termos MeSH secundário: Adulto
Feminino
Grécia/epidemiologia
Seres Humanos
Estimativa de Kaplan-Meier
Análise Multivariada
Estudos Retrospectivos
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Mês de entrada:1309
[Cu] Atualização por classe:130701
[Lr] Data última revisão:
130701
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:130702
[St] Status:MEDLINE
[do] DOI:10.1097/AOG.0b013e318291ef9a


  4 / 70 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23464691
[Au] Autor:Corben AD
[Ad] Endereço:Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. corbena@mskcc.org
[Ti] Título:Pathology of invasive breast disease.
[So] Source:Surg Clin North Am;93(2):363-92, 2013 Apr.
[Is] ISSN:1558-3171
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Invasive breast cancers constitute a heterogeneous group of lesions. Although the most common types are ductal and lobular, this distinction is not meant to indicate the site of origin within the mammary ductal system. The main purpose of the identification of specific types of invasive breast carcinoma is to refine the prediction of likely behavior and response to treatment also offered by the other major prognostic factors, including lymph node stage, histologic grade, tumor size, and lymphovascular invasion.
[Mh] Termos MeSH primário: Neoplasias da Mama/patologia
[Mh] Termos MeSH secundário: Adenocarcinoma Mucinoso/patologia
Adenocarcinoma Papilar/patologia
Biomarcadores Tumorais/metabolismo
Neoplasias da Mama/metabolismo
Carcinoma Adenoide Cístico/patologia
Carcinoma Neuroendócrino/patologia
Feminino
Seres Humanos
Invasividade Neoplásica
Neoplasias Ductais, Lobulares e Medulares/patologia
Prognóstico
Carga Tumoral
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers, Tumor)
[Em] Mês de entrada:1304
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:130308
[St] Status:MEDLINE


  5 / 70 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22581300
[Au] Autor:Gil EY; Jo UH; Jeong H; Whang YM; Woo OH; Cho KR; Seo JH; Kim A; Lee ES; Koh I; Kim YH; Park KH
[Ad] Endereço:Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea.
[Ti] Título:Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer.
[So] Source:Int J Oncol;41(2):611-20, 2012 Aug.
[Is] ISSN:1791-2423
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:Docetaxel is one of the most commonly used chemotherapeutic agents in breast cancer. To avert from significant toxicities with no clinical benefit, identification of predictive markers for response is one of the most important unsolved clinical needs. Therefore, the potential associations of RASSF1A hypermethylation and response to docetaxel-based chemotherapy were evaluated, and the underlying mechanism was studied. The expression of RASSF1A in breast cancer cell lines and tissues of normal breast, ductal carcinoma in situ (DCIS), and breast cancer (n=45) was analyzed by immunohistochemistry and western blot analysis. Immunohistochemical staining showed that the expression of RASSF1A was frequently lost in primary breast cancers and human breast cancer cell lines, while normal breast tissues or DCIS displayed moderate to strong expression. Furthermore, quantitative methylation analysis of the RASSF1A promoter region in 45 primary breast cancers revealed that RASSF1A was frequently methylated in primary breast cancers (≥20% methylation in 53% of the patients), and prospective analysis in patients with locally advanced or recurrent breast cancer showed that the mean level of methylation of RASSF1A was significantly higher in patients who did not respond to docetaxel-based chemotherapy (30.6±8.5%) than patients with partial or complete response (20.1±11.2%, p=0.042). Finally, in vitro studies showed that RASSF1A had cooperative activity in suppression of cancer cell growth and proliferation by enhancing docetaxel-induced cell cycle arrest. Our results suggest that hypermethylated RASSF1A is an important modulating factor for the efficacy of docetaxel-based chemotherapy in breast cancer.
[Mh] Termos MeSH primário: Antineoplásicos/farmacologia
Neoplasias da Mama/tratamento farmacológico
Metilação de DNA
Neoplasias Ductais, Lobulares e Medulares/tratamento farmacológico
Regiões Promotoras Genéticas
Taxoides/farmacologia
Moduladores de Tubulina/farmacologia
Proteínas Supressoras de Tumor/genética
[Mh] Termos MeSH secundário: Adulto
Antineoplásicos/uso terapêutico
Apoptose/efeitos dos fármacos
Sequência de Bases
Neoplasias da Mama/metabolismo
Proteínas de Ciclo Celular/metabolismo
Linhagem Celular Tumoral
Proliferação Celular
Regulação para Baixo
Epigênese Genética
Feminino
Pontos de Checagem da Fase G2 do Ciclo Celular/efeitos dos fármacos
Regulação Neoplásica da Expressão Gênica
Seres Humanos
Modelos Logísticos
Análise Multivariada
Neoplasias Ductais, Lobulares e Medulares/metabolismo
Análise de Sequência de DNA
Taxoides/uso terapêutico
Moduladores de Tubulina/uso terapêutico
Proteínas Supressoras de Tumor/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Cell Cycle Proteins); 0 (RASSF1 protein, human); 0 (Taxoids); 0 (Tubulin Modulators); 0 (Tumor Suppressor Proteins); 15H5577CQD (docetaxel)
[Em] Mês de entrada:1210
[Cu] Atualização por classe:130528
[Lr] Data última revisão:
130528
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120515
[St] Status:MEDLINE
[do] DOI:10.3892/ijo.2012.1470


  6 / 70 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:22472404
[Au] Autor:Menes TS; Zissman S; Golan O; Sperber F; Klausner J; Schneebaum S
[Ad] Endereço:Department of Surgery, Sourasky Medical Center, Tel Aviv, Israel. tehillahm@tasmc.health.gov.il
[Ti] Título:Yield of selective magnetic resonance imaging in preoperative workup of newly diagnosed breast cancer patients planned for breast conserving surgery.
[So] Source:Am Surg;78(4):451-5, 2012 Apr.
[Is] ISSN:1555-9823
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The role of routine preoperative magnetic resonance imaging (MRI) in newly diagnosed breast cancer patients planned for breast conserving surgery is presently being debated. In our medical center we practice selective use of preoperative MRI; we sought to examine the yield of MRI in this highly selected group of patients. A retrospective study of all newly diagnosed breast cancer patients presenting between January 2007 and July 2010 to the Tel Aviv Sourasky Medical Center (Tel Aviv, Israel) was completed. Patients planned for breast conserving surgery who underwent preoperative MRI were included in this study. Patients and tumor characteristics, indication for MRI, findings on MRI, consequent workup, and impact on surgical treatment were recorded. Association between preoperative characteristics and yield of MRI was examined. During the study period, 105 patients that were candidates for breast conserving surgery underwent preoperative evaluation with MRI. Use of breast MRI increased over time. Rates of mastectomy were stable throughout the study years. Dense mammogram was the most frequent (51, 68%) indication for MRI. Additional suspicious findings were found in 41 (39%) patients, prompting further workup including 36 biopsies in 25 patients, of which 22 (61%) were with cancer. These additional findings prompted a change in the surgical plan in a third of the patients. In most patients (92; 88%) clear margins were achieved. Limiting the use of MRI in the preoperative workup of breast cancer patients to a selected group of patients can increase the yield of MRI.
[Mh] Termos MeSH primário: Neoplasias da Mama/diagnóstico
Imagem por Ressonância Magnética
Mastectomia Segmentar
Neoplasias Ductais, Lobulares e Medulares/diagnóstico
Cuidados Pré-Operatórios
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Neoplasias da Mama/cirurgia
Técnicas de Apoio para a Decisão
Feminino
Seres Humanos
Meia-Idade
Neoplasias Ductais, Lobulares e Medulares/cirurgia
Estudos Retrospectivos
Resultado do Tratamento
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Em] Mês de entrada:1207
[Cu] Atualização por classe:120404
[Lr] Data última revisão:
120404
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120405
[St] Status:MEDLINE


  7 / 70 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22153085
[Au] Autor:Nizri E; Schneebaum S; Klausner JM; Menes TS
[Ad] Endereço:Department of Surgery, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
[Ti] Título:Current management practice of breast borderline lesions--need for further research and guidelines.
[So] Source:Am J Surg;203(6):721-5, 2012 Jun.
[Is] ISSN:1879-1883
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Breast borderline lesions are usually diagnosed on needle biopsies of imaging abnormalities. The natural history of these lesions is unclear, and the literature is divided on appropriate management. It was hypothesized that management varies among surgeons and may be associated with surgeon and practice characteristics. METHODS: A survey of 477 members of the American Society of Breast Surgeons was completed. Results were analyzed according to various surgeon and practice characteristics. RESULTS: Most respondents recommended routine excision for atypical ductal and lobular hyperplasia. Excision of radial scars and papillomas was much more variable, with only 50% recommending routine excision. Results differed by surgical dedication to breast surgery and fellowship training. Management of atypical ductal or lobular hyperplasia found at the margin varied significantly. The lack of a routine tumor board, low breast case volume, and low percentage of breast cases were associated with routine excision in these cases. CONCLUSIONS: Breast borderline lesions pose a clinical dilemma, with practice varying greatly among surgeons.
[Mh] Termos MeSH primário: Neoplasias da Mama/cirurgia
Mama/cirurgia
Neoplasias Ductais, Lobulares e Medulares/cirurgia
Padrões de Prática Médica/estatística & dados numéricos
Lesões Pré-Cancerosas/cirurgia
[Mh] Termos MeSH secundário: Mama/patologia
Feminino
Pesquisas sobre Serviços de Saúde
Seres Humanos
Hiperplasia/cirurgia
Modelos Logísticos
Análise Multivariada
Papiloma Intraductal/cirurgia
Guias de Prática Clínica como Assunto
Inquéritos e Questionários
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1207
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:111214
[St] Status:MEDLINE
[do] DOI:10.1016/j.amjsurg.2011.06.052


  8 / 70 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:20191065
[Au] Autor:Dietzel M; Baltzer PA; Vag T; Herzog A; Gajda M; Camara O; Kaiser WA
[Ad] Endereço:Institute of Diagnostic and Interventional Radiology, Friedrich-Schiller-University Jena, Erlanger Allee 101, D-07740 Jena, Germany. matthias.dietzel@med.uni-jena.de
[Ti] Título:The adjacent vessel sign on breast MRI: new data and a subgroup analysis for 1,084 histologically verified cases.
[So] Source:Korean J Radiol;11(2):178-86, 2010 Mar-Apr.
[Is] ISSN:2005-8330
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The adjacent vessel sign (AVS) is a descriptor for differentiating malignant from benign breast lesions on breast MRI (bMRI). This investigation was designed to verify the previous reports on the diagnostic accuracy of AVS and to assess correlation between AVS, histopathological diagnosis, lesion size and lesion grade. MATERIALS AND METHODS: This study was approved by the local ethical committee. Experienced radiologists evaluated 1,084 lesions. The exclusion criteria were no histological verification after bMRI and breast interventions that were done up to one year before bMRI (surgery, core biopsy, chemo- or radiation therapy). The native and dynamic contrast-enhanced T1-weighted series were acquired using standardized protocols. The AVS was rated positive if a vessel leading to a lesion could be visualized. Prevalence of an AVS was correlated with the lesions' size, grade and histology using Chi-square-tests. RESULTS: The AVS was significantly associated with malignancy (p < 0.001; sensitivity: 47%, specificity: 88%, positive-predictive-value [PPV]: 85%). Malignant lesions > 2 cm more often presented with an AVS than did those malignant lesions < 2 cm (p < 0.0001; sensitivity: 65%, PPV: 90%). There was no correlation of the AVS with the tumor grade. The prevalence of an AVS didn't significantly differ between invasive lobular carcinomas versus ductal carcinomas. In situ cancers were less frequently associated with an AVS (p < 0.001). CONCLUSION: The adjacent vessel sign was significantly associated with malignancy. Thus, it can be used to accurately assess breast lesions on bMRI. In this study, the AVS was particularly associated with advanced and invasive carcinomas.
[Mh] Termos MeSH primário: Neoplasias da Mama/patologia
Mama/patologia
Imagem por Ressonância Magnética/métodos
Neoplasias Ductais, Lobulares e Medulares/patologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Meios de Contraste
Diagnóstico Diferencial
Feminino
Gadolínio DTPA
Seres Humanos
Aumento da Imagem/métodos
Meia-Idade
Variações Dependentes do Observador
Valor Preditivo dos Testes
Reprodutibilidade dos Testes
Sensibilidade e Especificidade
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contrast Media); K2I13DR72L (Gadolinium DTPA)
[Em] Mês de entrada:1005
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:100302
[St] Status:MEDLINE
[do] DOI:10.3348/kjr.2010.11.2.178


  9 / 70 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:19952761
[Au] Autor:Harirchi I; Karbakhsh M; Montazeri A; Ebrahimi M; Jarvandi S; Zamani N; Momtahen AJ; Kashefi A; Zafarghandi MR
[Ad] Endereço:Cancer Institute, Cancer Research Center, Tehran University of Medical Sciences, Tehran, Iran. harirchi@sina.tums.ac.ir
[Ti] Título:Decreasing trend of tumor size and downstaging in breast cancer in Iran: results of a 15-year study.
[So] Source:Eur J Cancer Prev;19(2):126-30, 2010 Mar.
[Is] ISSN:1473-5709
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The aim of this cross-sectional study was to show the characteristics of breast cancer across a period of 15 years according to pathological records in Tehran, Iran. In the year 1985, a 20-year study was designed and developed in five major hospitals in Tehran to study the burden and characteristics of breast cancer in Iran. This study is based on the data collected from 1986 through 2000. SPSS version 13 was used for statistical analysis. In this study, 1612 female breast cancer records were reviewed. The mean age of patients was 47.95+/-12.42 years with a median of 47 years. Over the study period, the proportion of tumors diagnosed at T2 increased with a decline in the proportion of T3 cases. Similarly, the percentage of stage II cases at diagnosis increased, whereas stage III decreased. We detected a decrease in tumor size and downstaging of female breast cancer in Tehran, Iran. This can be attributed to the overall improvement in the level of health in Iran and also educational activities that teach women how to perform breast self-exam and when and why to ask for breast examination.
[Mh] Termos MeSH primário: Adenocarcinoma Mucinoso/patologia
Neoplasias da Mama/patologia
Neoplasias Ductais, Lobulares e Medulares/patologia
[Mh] Termos MeSH secundário: Adenocarcinoma Mucinoso/epidemiologia
Adulto
Neoplasias da Mama/epidemiologia
Estudos Transversais
Feminino
Seres Humanos
Irã (Geográfico)/epidemiologia
Meia-Idade
Estadiamento de Neoplasias
Neoplasias Ductais, Lobulares e Medulares/epidemiologia
Prognóstico
Sistema de Registros
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1004
[Cu] Atualização por classe:100201
[Lr] Data última revisão:
100201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:091203
[St] Status:MEDLINE
[do] DOI:10.1097/CEJ.0b013e328333d0b3


  10 / 70 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:19840953
[Au] Autor:Niwinska A; Murawska M; Pogoda K
[Ad] Endereço:Department of Breast Cancer and Reconstructive Surgery, The Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland. alphaonetau@poczta.onet.pl
[Ti] Título:Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT).
[So] Source:Ann Oncol;21(5):942-8, 2010 May.
[Is] ISSN:1569-8041
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Patients with breast cancer brain metastasis are a heterogeneous group in relation to tumor biology and outcome. MATERIALS AND METHODS: The group of 222 breast cancer patients with brain metastasis was divided into three biological subgroups. The propensity of biological subtypes for metastases to the brain and survivals depending on biological subtype, recursive partitioning analysis of Radiation Therapy Oncology Group (RPA RTOG) prognostic class and the use of systemic treatment after whole-brain radiotherapy were assessed. RESULTS: The rate of patients with triple-negative, human epidermal growth factor receptor 2 (HER2)-positive and luminal breast cancer with brain metastases was 28%, 53% and 19%, respectively. Median survival from brain metastases in triple-negative, HER2-positive and luminal subtype was 3.7, 9 and 15 months, respectively. Median survival from brain metastases in RPA RTOG prognostic class I, II and III was 15, 11 and 3 months, respectively. In the luminal and in the triple-negative subtype, systemic therapy prolonged survival from 3 to 14 months and from 3 to 4 months, respectively. In HER2-positive subtype, median survival without further treatment, after chemotherapy and after chemotherapy with targeted therapy were 3, 8 and 11 months, respectively. CONCLUSIONS: HER2-positive and triple-negative breast cancers have special predilection for metastases to the brain. Survival from brain metastases depended on performance status and the use of systemic treatment.
[Mh] Termos MeSH primário: Neoplasias Encefálicas/mortalidade
Neoplasias da Mama/mortalidade
Neoplasias da Mama/patologia
Irradiação Craniana
Neoplasias Ductais, Lobulares e Medulares/mortalidade
[Mh] Termos MeSH secundário: Adulto
Idoso
Neoplasias Encefálicas/metabolismo
Neoplasias Encefálicas/radioterapia
Neoplasias Encefálicas/secundário
Neoplasias da Mama/metabolismo
Neoplasias da Mama/radioterapia
Estudos de Coortes
Feminino
Seguimentos
Seres Humanos
Meia-Idade
Neoplasias Ductais, Lobulares e Medulares/metabolismo
Neoplasias Ductais, Lobulares e Medulares/radioterapia
Neoplasias Ductais, Lobulares e Medulares/secundário
Receptor ErbB-2/metabolismo
Estudos Retrospectivos
Taxa de Sobrevida
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
EC 2.7.10.1 (Receptor, ErbB-2)
[Em] Mês de entrada:1008
[Cu] Atualização por classe:161017
[Lr] Data última revisão:
161017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:091021
[St] Status:MEDLINE
[do] DOI:10.1093/annonc/mdp407



página 1 de 7 ir para página                  
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde